Mark R. Dowling - Concepedia

Author

Mark R. Dowling

Walter and Eliza Hall Institute of Medical Research ORCID

Also Known As

, Dowling, Mark R., M Dowling, M R Dowling, M. R. Dowling, M.R. DOWLING, M.R. Dowling, Mark Dowling, Mark R Dowling, Mark R. Dowling

125

Publications

3.8K

Citations

H-Index

100

Concepts

All Affiliations

Walter and Eliza Hall Institute of Medical Research The University of Melbourne The University of Queensland Novartis (United Kingdom)Peter MacCallum Cancer Centre

About

Mark R. Dowling is an author at Walter and Eliza Hall Institute of Medical Research specializing in medicine, engineering, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	910
2	Engineering	10	11	778
3	Natural Sciences	8	8	419
4	Allergy	2	2	383
5	Health Sciences	1	1	57

Mark R. Dowling

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Quantum Computation as Geometry Michael A. Nielsen, Mark R. Dowling, Mile Gu, Science	2006	531
Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion Julia M. Marchingo, Andrey Kan, Robyn M. Sutherland, Science T-regulatory CellImmunologyImmunologic MechanismAntigen ProcessingCd4 T Cell Responses	2014	205
Activation-Induced B Cell Fates Are Selected by Intracellular Stochastic Competition Ken R. Duffy, Cameron Wellard, John Markham, Science	2012	201
Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets Emma C. Josefsson, Chloé James, Katya J. Henley, The Journal of Experimental Medicine ApoptosisImmunologyBlood CellCell DeathPathology	2011	184
A model of immune regulation as a consequence of randomized lymphocyte division and death times Edwin D. Hawkins, Marian L. Turner, Mark R. Dowling, Proceedings of the National Academy of Sciences Adaptive Immune SystemAdaptive Immune ResponseImmune RegulationImmunologyImmunologic Mechanism	2007	178
In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action Cliff H. Battram, Steven J. Charlton, Bernard Cuenoud, Journal of Pharmacology and Experimental Therapeutics	2006	161
Optimal control, geometry, and quantum computing Michael A. Nielsen, Mark R. Dowling, Mile Gu, Physical Review A Quantum ScienceOptimal ControlQuantum ComputingGate ComplexityQuantum Gate Complexity	2006	141
The geometry of quantum computation Mark R. Dowling, Morten Nielsen Quantum Information and Computation Quantum ScienceEngineeringQuantum ComputingQuantum Optimization AlgorithmQuantum Oracle Relative	2008	134
Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M <sub>3</sub> receptor Mark R. Dowling, Steven J. Charlton British Journal of Pharmacology	2006	125
Exploring the Mechanism of Agonist Efficacy: A Relationship between Efficacy and Agonist Dissociation Rate at the Muscarinic M3 Receptor David A. Sykes, Mark R. Dowling, Steven J. Charlton Molecular Pharmacology	2009	121

Page 1